The earnings call highlighted significant achievements such as FDA clearance and a strong financial position, alongside strategic clinical trial approvals. However, there are challenges related to the slow rollout, capital needs, and competition from established players. The sentiment is slightly positive due to the weight of key achievements.

Company Guidance -

Q2 2025

During the Monogram Technologies First Quarter 2025 Financial Results and Business Update Conference Call, the company provided several key metrics and guidance. As of March 31, 2025, Monogram held $13.3 million in cash with an operating cash flow of $2.3 million for the quarter, translating into a monthly cash burn of approximately $0.8 million, down from last year's $1.1 million to $1.2 million. The company projects a monthly cash burn rate of $1 million for the remainder of the year, with additional spending of $1.2 million anticipated for the clinical trial over six to nine months. Monogram has 27 full-time employees and no traditional debt, positioning itself favorably for future growth. Notably, the company achieved FDA 510(k) clearance for its mBôs TKA system and received regulatory approval from India's CDSCO to initiate a multicenter clinical trial. These developments, along with ongoing enhancements to the robotic system and strategic partnerships, are expected to drive Monogram's commercial growth and position it as a leader in orthopedic surgery innovation.

FDA Clearance Achieved

Monogram Technologies received 510(k) clearance from the FDA for the mBôs TKA system, marking a defining milestone in the company's history.

Strong Financial Position

The company reports $13.3 million in cash with a reduced monthly cash burn rate of $0.8 million, down from $1.1 to $1.2 million last year. The company has no traditional debt and minimal short-term obligations.

Clinical Trial Approval in India

Regulatory approval was obtained from the CDSCO to initiate a multicenter clinical trial in India, marking the world's first autonomous saw-based robotic total knee surgeries on live patients.

Technology and Market Position

The mBôs surgical system is the only hands-free autonomous saw-based total knee robot cleared by the FDA, positioning Monogram at the forefront of orthopedic surgery innovations.

Monogram Orthopaedics Inc (MGRM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MGRM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.09 / -	-0.11	―	―	―
May 14, 2025	2025 (Q1)	-0.12 / -0.10	-0.11	9.09% (<+0.01)	―
Mar 12, 2025	2024 (Q4)	-0.11 / -0.08	0.09	-188.89% (-0.17)
Nov 14, 2024	2024 (Q3)	-0.12 / -0.16	-0.034	-370.59% (-0.13)	―	―
Aug 14, 2024	2024 (Q2)	-0.09 / -0.11	-0.272	59.56% (+0.16)	―	―
May 14, 2024	2024 (Q1)	-0.12 / -0.11	-0.132	16.67% (+0.02)	―
Mar 15, 2024	2023 (Q4)	- / 0.09	-0.25	136.00% (+0.34)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MGRM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$2.50	$2.72	+8.80%
Mar 12, 2025	$2.32	$2.31	-0.43%
Nov 14, 2024	$2.01	$2.05	+1.99%
Aug 14, 2024	$2.70	$2.79	+3.33%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Monogram Orthopaedics Inc (MGRM) report earnings?

Monogram Orthopaedics Inc (MGRM) is schdueled to report earning on Aug 13, 2025, Before Open (Confirmed).

What is Monogram Orthopaedics Inc (MGRM) earnings time?

Monogram Orthopaedics Inc (MGRM) earnings time is at Aug 13, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MGRM EPS forecast?

MGRM EPS forecast for the fiscal quarter 2025 (Q2) is -0.09.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing